Growth in emerging markets may be slowing, but pharma sales there are still outpacing those everywhere else. And if recent numbers are any indication, AstraZeneca ($AZN) is topping its rivals for emerging markets expansion. AstraZeneca's sales in the developing world jumped by 14% over the last four quarters--four percentage points ahead of next-place companies Pfizer ($PFE) and Sanofi ($SNY)--and beat all comers quarter-by-quarter as well.
